Mesalazine/Sodium Hyaluronate

美沙拉嗪/透明质酸钠

Report date: 2024/04/01 20:04:33

Base Information

Drug NameMesalazine/Sodium Hyaluronate
Drug Alias Name美沙拉嗪+透明质酸钠Sodium Hyaluronate/Mesalazine透明质酸钠+美沙拉嗪Mesalamine/Hyaluronate sodium透明质酸钠/美沙拉嗪 +[10] 
ClassificationSmall molecules
Mechanisms of ActionProtein phosphatase 2A inhibitorsHyaluronic acid replacements
TargetsProtein phosphatase 2AHyaluronic acid
Therapy Area/IndicationsColitis, UlcerativeColitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaItalyMainland China
CombinationsYes MesalazineSodium Hyaluronate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHoly Stone Healthcare Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Collins Likang Medical Research Co LtdHoly Stone Healthcare Co Ltd
Inactive CompaniesN/A
Active IndicationsColitis, UlcerativeColitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A